Pyxis Oncology shares are trading lower after the company announced that it will acquire Apexigen for an implied value of $0.64 per share.
Portfolio Pulse from Benzinga Newsdesk
Pyxis Oncology announced it will acquire Apexigen for an implied value of $0.64 per share, causing Pyxis shares to trade lower.
May 24, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pyxis Oncology shares are trading lower after announcing the acquisition of Apexigen for $0.64 per share.
The acquisition announcement has led to a decline in Pyxis Oncology's share price. Investors may be concerned about the cost of the acquisition or its potential impact on the company's financials, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100